Cytokinetics CYTK Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Cytokinetics's stock issuance proceeds?
- Cytokinetics (CYTK) reported stock issuance proceeds of $11.35M in Q1 2026.
- What does stock issuance proceeds mean?
- Cash received from selling company shares to investors or employees.
- How do you interpret stock issuance proceeds?
- An increase indicates successful capital raising or high employee participation in equity plans, while a decrease may suggest reduced reliance on equity financing.
- How does stock issuance proceeds compare across companies?
- Standard across all public companies; biotech firms often show higher volatility due to frequent secondary offerings.